Analyzing R&D Budgets: Pharming Group N.V. vs Perrigo Company plc

R&D Trends: Pharming's Surge vs. Perrigo's Decline

__timestampPerrigo Company plcPharming Group N.V.
Wednesday, January 1, 201415250000014182353
Thursday, January 1, 201518780000015503028
Friday, January 1, 201618400000016183585
Sunday, January 1, 201716770000022382849
Monday, January 1, 201821860000033038206
Tuesday, January 1, 201918740000031777040
Wednesday, January 1, 202017770000041464134
Friday, January 1, 202112200000067178053
Saturday, January 1, 202212310000052531000
Sunday, January 1, 202312250000068914000
Loading chart...

Igniting the spark of knowledge

The Evolution of R&D Investments in the Pharmaceutical Sector

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Pharming Group N.V. and Perrigo Company plc have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Perrigo's R&D expenses have seen a decline of approximately 20%, dropping from a peak in 2018. In contrast, Pharming Group N.V. has increased its R&D spending by nearly 385% over the same period, reflecting a robust commitment to innovation.

This divergence highlights a strategic shift in the industry, where smaller firms like Pharming are aggressively investing in R&D to carve out a niche in the competitive market. As the pharmaceutical sector continues to grow, understanding these investment trends is crucial for stakeholders aiming to predict future market leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025